SEARCH

SEARCH BY CITATION

References

  • 1
    Fernandez MP, Redvanly RD. Primary malignant neoplasms. Radiol Clin Noth Am 1998; 36: 33348.
  • 2
    Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004; 127: 516.
  • 3
    El-Serag HB, Ason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United states. Hepatology 2001; 33: 625.
  • 4
    Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 52938.
  • 5
    Barbara L, Benzi G, Giani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors in tumour growth rate and patient survival. Hepatology 1992; 16: 1327.
  • 6
    Llovet JM. Updated treatment approach to hepatocellular carcinoma. Gastroenterol 2005; 40: 22535.
  • 7
    Schafer DF, Sorrel MF. Hepatocellular carcinoma. Lancet 1999; 353: 12537.
  • 8
    Hussain SM, Zondervan PE, Izermans JNM, et al. Benign versus malignant hepatic nodules: MR-imaging findings with pathologic correlation. Radiographics 2002; 22: 102336.
  • 9
    Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep carcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Path 1991; 22: 1728.
  • 10
    Choi BI, Takayasu K, Han MC. Small hepatocellular carcinomas and associated nodular lesions of the liver: pathology, pathogenesis and imaging findings. Am J Roentgenol 1993; 160: 117787.
  • 11
    Torzilli G, Minagawa M, Takayama T, et al. Accurate preoperative evaluation of liver mass lesions without fineneedle biopsy. Hepatology 1999; 30: 88993.
  • 12
    Bruix J, Shermann M. Practice guidelines committee, American association for the study of liver diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 120836.
  • 13
    Terjung B, Lemnitzer I, Dumoulin FL, et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 2003; 67: 13845.
  • 14
    Stewart CJR, Coldewey J, Stewart IS. Comparison of fine needle aspiration cytology and needle core biopsy in the diagnosis of radiologically detected abdominal lesions. J Clin Pathol 2002; 55: 937.
  • 15
    Fornari F, Civardi G, Cavanna L, et al. Ultrasonically guided fine-needle aspiration biopsy: a highly diagnostic procedure or hepatic tumors. Am J Gastroenterol 1990; 85: 100913.
  • 16
    McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16 year population based study. Hepatology 2000; 32: 8426.
  • 17
    Kemp W, Pianko S, Nguyen S, et al. Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease. J Gastroenterol Hepatol 2005; 20: 87281.
  • 18
    Terminology of nodular hepatic lesions. International Working Party. Hepatology 1995; 22: 98393.
  • 19
    Bennett GL, Krinsky GA, Abitbol RJ, et al. Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis: correlation of pretransplantation sonography and liver explant pathology in 200 patients. Am J Roentgenol 2002; 179: 7580.
  • 20
    Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006; 101: 51323.
  • 21
    Ando E, Kuromatsu R, Tanaka M, et al. Surveillance program for early detection of hepatocellular carcinoma in Japan: results of specialized department of liver disease. J Clin Gastroenterol 2006; 40: 9428.
  • 22
    Burns PN. Interpreting and analyzing the Doppler examination. In: TaylorKJW, BurnsPN, WellsPNT, eds. Clinical applications of Doppler ultrasound. New York, NY: Raven, 1995; 5598.
  • 23
    Wells PNT. Basic principles and Doppler physics. In: TaylorKJW, BurnsPN, WellsPNT, eds. Clinical Applications of Doppler Ultrasound. New York, NY: Raven, 1995; 117.
  • 24
    Lu MD, Yu XL, Li AH, et al. Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI in monitoring percutaneous thermal ablation procedure in patients with hepatocellular carcinoma: a multi-center study in China. Ultrasound Med Biol 2007; 33: 173649.
  • 25
    Chen MH, Yang W, Yan K, et al. The role of contrast-enhanced ultrasound in planning treatment protocols for hepatocellular carcinoma before radiofrequency ablation. Clin Radiol 2007; 62: 75260.
  • 26
    Kisaka Y, Hirooka M, Kumagi T, et al. Usefulness of contrast-enhanced ultrasonography with abdominal virtual ultrasonography in assessing therapeutic response in hepatocellular carcinoma treated with radiofrequency ablation. Liver Int 2006; 26: 12417.
  • 27
    Maruyama H, Kobayashi S, Yoshizumi H, et al. Application of percutaneous ultrasound-guided treatment for ultrasonically invisible hypervascular hepatocellular carcinoma using microbubble contrast agent. Clin Radiol 2007; 62: 66875.
  • 28
    Torzilli G, Palmisano A, Del Fabbro D, et al. Contrast-enhanced intraoperative ultrasonography during surgery for hepatocellular carcinoma in liver cirrhosis: is it useful or useless? A prospective cohort study of our experience. Ann Surg Oncol 2007; 14: 134755.
  • 29
    Wang Z, Tang J, An L, et al. Contrast-enhanced ultrasonography for assessment of tumor vascularity in hepatocellular carcinoma. J Ultrasound Med 2007; 26: 75762.
  • 30
    Ding H, Kudo M, Onda H, et al. Contrast-enhanced subtraction harmonic sonography for evaluating treatment response in patients with hepatocellular carcinoma. Am J Roentgenol 2001; 176: 6616.
  • 31
    Numata K, Tanaka K, Kiba T, et al. Correlation between hepatic tumor index on color Doppler sonography and tumor vessels on arteriography in large hepatocellular carcinomas. Cancer Detect Prev 1999; 23: 496505.
  • 32
    Brancatelli G, Federle MP, Grazioli L, Carr BI. Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathologic findings in 39 U.S. residents. Radiology 2002; 222: 8994.
  • 33
    Tublin ME, Dodd GD III, Baron RL. Benign and malignant portal vein thrombosis: differentiation by CT characteristics. Am J Roentenol 1997; 168: 71923.
  • 34
    Murakami T, Kim T, Takahashi S, Nakamura H. Hepatocellular carcinoma: multidetector row helical CT. Abdom Imaging 2002; 27: 13946.
  • 35
    Freeny PC, Baron RL, Teefey SA. Hepatocellular carcinoma: reduced frequency of typical findings with dynamic contrastenhanced CT in a non-Asian population. Radiology 1992; 182: 1438.
  • 36
    Iannaccone R, Piacentini F, Murakami T, et al. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: helical CT and MR imaging findings with clinical- pathologic comparison. Radiology 2007; 243: 42330.
  • 37
    Peterson MS, Baron RL. Radiologic diagnosis of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 12348.
  • 38
    Mitsuzaki K, Yamashita Y, Ogata I, et al. Multiple-phase helical CT of the liver for detecting small hepatomas in patients with liver cirrhosis: contrast-injection protocol and optimal timing. Am J Roentgenol 1996; 167: 75357.
  • 39
    Yamashita Y, Mitsuzaki K, Yi T, et al. Small hepatocellular carcinoma in patients with chronic liver damage: prospective comparison of detection with dynamic MR imaging and helical CT of the whole liver. Radiology 1996; 200: 7984.
  • 40
    Zhao H, Yao JL, Wang Y, Zhou KR. Detection of small hepatocellular carcinoma: comparison of dynamic enhancement magnetic resonance imaging and multiphase multirow-detector helical CT scanning. World J Gastroenterol 2007; 13: 12526.
  • 41
    Sahani DV, Holakere NS, Mueller PR, Zhu AX. Advanced hepatocellular Carcinoma: CT perfusion of liver and tumor tissue – initial experience. Radiology 2007; 1243: 73643.
  • 42
    Su Q, Benner A, Hofmann WJ, et al. Human hepatic preneoplasia: phenotypes and proliferation kinetics of foci and nodules of altered hepatocytes and their relationship to liver cell dysplasia. Virchow's Archiv 1997; 431: 3916.
  • 43
    Saeki R, Nagai H, Kaneko S, et al. Intratumoral genomic heterogeneity in human hepatocellular carcinoma detected by restriction landmark genomic scanning. J Hepatol 2000; 33: 99105.
  • 44
    Matsui O, Kadoya M, Kanemyama T, et al. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 1991; 178: 4937.
  • 45
    Krinksy GA, Israel G. Nondysplastic nodules that are hyperintense on T1 weighted gradient-echo MR Imaging. Am J Roentenol 2003; 180: 10237.
  • 46
    Semelka R, Helmberger T. Contrast agents for MR-imaging of the liver. Radiology 2001; 218: 2738.
  • 47
    Hahn PF, Saini S. Liver specific MR imaging contrast agents. Radiol Clin North Am 1998; 36: 28797.
  • 48
    Spinazzi A, Lorusso V, Pirovno G, et al. Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 1998; 5: 869.
  • 49
    Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions in MRI. A multicenter comparison of Gd-EOB-DTPA with introperative findings. Radiology 2004; 230: 26675.
  • 50
    Pirovano G, Vanzulli A, Marti-bonmati L, et al. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR-imaging in the detection and characterization of focal liver lesions. Am J Roentenol 2000; 175: 111120.
  • 51
    Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest Radiol 2000; 35: 2534.
  • 52
    Manfredi R, Maresca G, Baron RL, et al. Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenete dimeglumine (GD-BOPTA). J Magn Reson Imaging 1999; 9: 70410.
  • 53
    Rofsky NM, Weinreb JC, Bernardino ME, et al. Hepatocellular tumors: characterization with MN-DPDP enhanced imaging. Radiology 1993; 188: 539.
  • 54
    Murakami T, Baron RL, Peterson MS, et al. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP). Radiology 1996; 20: 6977.
  • 55
    Coffin CM Diche T, Mahfouz AE, et al. Benign and malignant hepatocellular tumors: evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging. Eur Radiol 1999; 9: 4449.
  • 56
    Ros PR, Freeny PC, Harms SE, et al. Hepatic MR imaging with ferumoxide: a multicentric clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 1995; 196: 4818.
  • 57
    Namkung S, Zech CJ, Helmberger T, et al. Superparamagnetic iron oxide (SPIO) enhanced liver MRI with ferucarbotran: efficacy for characterization of focal liver lesions. J Magn Reson Imaging 2007; 25: 75565.
  • 58
    Yammamoto H, Yamashita Y, Yoshimatsu S, et al. Hepatocellular carcinoma in cirrhotic livers detection with unenhanced and iron-oxide enhanced MR-imaging. Radiology 1995; 196: 10612.
  • 59
    Vogl TJ, Hammerstingl R, Schwarz W, et al. Superparamagnetic iron oxide-enhanced versus gadolinium enhanced MR imaging for differential diagnosis of focal liver lesions. Radiology 1996; 198: 8817.
  • 60
    Kim SH, Choi D, Kim SH, et al. Ferucarbotran-enhanced MRI versus triple phase MDCT for the preoperative detection of hepatocellular carcinoma. Am J Roentgenol 2005; 184: 106976.
  • 61
    Hussain HK, Syed I, Nghiem HV, et al. T2 weighted MR imaging in the assessment of cirrhotic liver. Radiology 2004; 230: 63744.
  • 62
    Kondo H, Kanemasuta M, Itoh K, et al. Does T2weighted MR imaging really add no value in detection and characterization of focal lesions in cirrhotic liver? Radiology 2005; 234: 63840.
  • 63
    Hecht EM, Holland AE, Israel GM, et al. Hepatocellular carcinoma in the cirrhotic liver: Gadolinium – enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis. Radiology 2006; 239: 43947.
  • 64
    Holland AE, Hecht EM, Hahn WY, et al. Importance of small (≤20 mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver. Radiology 2005; 237: 93844.
  • 65
    Jeong YY, Mitchell DG, Kamishima T. Small (>20 mm) enhancing hepatic nodules seen on arterial phase MR imaging of the cirrhotic liver: clinical implications. Am J Roentgenol 2002; 178: 132734.
  • 66
    Kim YK, Lee YH, Kim CS, Han YM. Added diagnostic value of T2 weighted MR-imaging to gadolinium-enhanced three dimensional dynamic MR imaging for the detection of small hepatocellular carcinomas. Eur J Radiol 2007; Epub ahead of print.
  • 67
    Lauenstein TC, Salman K, Morreira R, et al. Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center based experience. Am J Roentgenol 2007; 189: 66370.
  • 68
    Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development and gadolinium exposure. Clin J Am Soc Nephrol 2007; 2: 2647.
  • 69
    Khan MA, Coms CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000; 32: 7927.
  • 70
    Trojan J, Schroeder O, Raedle J, et al. Fluorine -18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 33149.
    Direct Link:
  • 71
    Ho CL, Chen S, Yeung DW, Cheng TK. Dual tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007; 48: 9029.